Olon Group announces the acquisition of GTP Bioways Group

MILAN, July 03, 2024 (GLOBE NEWSWIRE) — GTP Bioways Group is a French company operating as a Biotech CDMO (Contract Developing and Manufacturing Organisation), specialising in R&D services, process development and production of monoclonal antibodies, enzymes, proteins, nanomedicines, ADCs and F&F. GTP Bioways Group, with multiple sites in France, specialises in providing comprehensive services to biopharmaceutical companies. From preclinical development to commercial stages, the group focuses on using cutting-edge technologies to advance innovative therapies.

GTP Bioways Group’s services are seamlessly integrated with those of the Olon Biotech division. This integration allows Olon Biotech to expand and diversify its technology offering, supporting all stages of the lifecycle, from R&D and preclinical phases to industrialization, including microbial and mammalian fermentation and biotherapeutics. In addition, Olon Biotech will provide comprehensive services for the development and production of innovative ADC classes, offering a complete solution from mAbs to linkers, payloads, conjugation and fill and finish processes.

GTP Bioways operates a total of four sites in France (Toulouse, Labège, Veyre-Monton and Saint-Julien-en-Genevois) dedicated to development, clinical trials and cGMP manufacturing. The head office is based in Toulouse.

All four centres operate to the highest quality standards, in accordance with GMP standards and are regularly inspected by the relevant regulatory authorities.

The business areas on which GTP Bioways focuses include biologics manufacturing and ADC manufacturing (using mammalian and microbial fermentation technology), nanomedicine manufacturing, fill and finish and analytical development – ​​including HCPs and immunoassays. In particular, the company has consolidated a strong expertise in the business areas in which it operates. This is evidenced by a significant number of successfully developed biological processes, the management of a wide and diversified range of expression systems (mammalian, bacterial, yeast, insect cells) and molecules (mAbs, antibody fragments, cytokines, fusion proteins, enzymes, antigens). In addition, the group has significant expertise in bioconjugation and fill and finish. The CDMO services offered constitute an integrated platform capable of supporting customers from drug discovery to the entire development process, with a particular focus on the preclinical phase, Phase I and Phase II.

Since its creation, Olon Group has always pursued a strategy of growth, consolidation and expansion in the global market, both through internal development and strategic acquisitions. Each acquired company has brought valuable expertise, strengthening Olon’s technological capabilities. In line with this strategy and with the aim of advancing its innovative and high-tech offerings for its customers, Olon has acquired GTP Bioways Group. GTP Bioways Group’s specific capabilities to fully support CDMO biotechnology projects, also in the early phase of new molecule development (preclinical, phase I and phase II), perfectly complement Olon’s current assets, to enrich and expand the offering to customers.

The story continues

“The acquisition of the GTP Bioways Group implies a strong and significant strengthening of Olon’s service portfolio with the aim of creating new business opportunities, acquiring new customers and high-potential markets and, ultimately, continuing the company’s growth,” declared Paolo Tubertini, CEO of the Olon Group.

In Q3 2024, Olon will complete its €25 million investment in an extremely high containment facility, fully dedicated to the development and production of highly potent APIs – payloads and payload binders for antibody-drug conjugates (ADCs). Olon leverages over four decades of experience in the manufacturing of cytotoxic products. With the acquisition of GTP Bioways, Olon Biotech will be able to offer comprehensive services for ADC development and production, capable of providing everything from mAbs to binders, payloads, conjugation and fill and finish.

Contact details – Sabrina Spina, Olon Press Office. [email protected] / +39 338 6674289